jaclyn
New member
- Joined
- Jun 4, 2018
- Messages
- 8
- Reason
- Loved one DX
- Diagnosis
- 04/2017
- Country
- US
- State
- NY
- City
- NYC
Thought you guys might be interested to hear how the Brainstorm conference call went today. Seems like the CEO Chaim Lebovits really wants to make NurOwn available but the logistics are up in the air and nothing is confirmed:
https://www.biocentury.com/bc-extra.../brainstorm-considering-right-try-als-therapy
Some key takeaways:
---Lebovits declined to estimate the cost for NurOwn beyond saying that cost of manufacturing and delivering the therapy is similar to CAR T cancer therapies. Yescarta, a CAR T therapy from the Kite Pharma Inc. unit of Gilead Sciences Inc., has a wholesale acquisition cost (WAC) of $373,000
---'On the conference call, he said BrainStorm “won’t go forward [with providing access under right to try] unless we have at least a partial answer to those who cannot afford it.”'
---He also said that if it provides NurOwn under right to try, BrainStorm will charge for the therapy. The law does not restrict companies’ abilities to charge for unapproved therapies.
---He told BioCentury the company could potentially offer NurOwn under right to try to 40 or 50 patients per year.
---BrainStorm is consulting ethicists, patients and clinicians to determine which patients would be given access if the company decides to make it available under right to try, Lebovits told BioCentury.
https://www.biocentury.com/bc-extra.../brainstorm-considering-right-try-als-therapy
Some key takeaways:
---Lebovits declined to estimate the cost for NurOwn beyond saying that cost of manufacturing and delivering the therapy is similar to CAR T cancer therapies. Yescarta, a CAR T therapy from the Kite Pharma Inc. unit of Gilead Sciences Inc., has a wholesale acquisition cost (WAC) of $373,000
---'On the conference call, he said BrainStorm “won’t go forward [with providing access under right to try] unless we have at least a partial answer to those who cannot afford it.”'
---He also said that if it provides NurOwn under right to try, BrainStorm will charge for the therapy. The law does not restrict companies’ abilities to charge for unapproved therapies.
---He told BioCentury the company could potentially offer NurOwn under right to try to 40 or 50 patients per year.
---BrainStorm is consulting ethicists, patients and clinicians to determine which patients would be given access if the company decides to make it available under right to try, Lebovits told BioCentury.
Last edited: